Aberdeen Group plc Increases Stock Position in Intuitive Surgical, Inc. $ISRG

Aberdeen Group plc boosted its stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 0.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 325,630 shares of the medical equipment provider’s stock after purchasing an additional 725 shares during the quarter. Aberdeen Group plc owned about 0.09% of Intuitive Surgical worth $176,951,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Chilton Capital Management LLC raised its position in shares of Intuitive Surgical by 614.3% during the 1st quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider’s stock valued at $25,000 after buying an additional 43 shares in the last quarter. Elite Financial Inc. purchased a new stake in shares of Intuitive Surgical during the 1st quarter valued at about $26,000. LFA Lugano Financial Advisors SA purchased a new stake in shares of Intuitive Surgical during the 1st quarter valued at about $30,000. TD Capital Management LLC raised its position in shares of Intuitive Surgical by 300.0% during the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 45 shares in the last quarter. Finally, 1248 Management LLC purchased a new stake in shares of Intuitive Surgical during the 1st quarter valued at about $30,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG stock opened at $429.59 on Friday. The company has a market capitalization of $154.00 billion, a P/E ratio of 59.91, a P/E/G ratio of 4.66 and a beta of 1.61. The company’s 50-day simple moving average is $458.68 and its two-hundred day simple moving average is $497.98. Intuitive Surgical, Inc. has a one year low of $425.00 and a one year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping analysts’ consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion for the quarter, compared to the consensus estimate of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company’s revenue for the quarter was up 21.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.78 EPS. On average, research analysts expect that Intuitive Surgical, Inc. will post 6.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other Intuitive Surgical news, EVP Myriam Curet sold 4,500 shares of the company’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the transaction, the executive vice president directly owned 353 shares in the company, valued at $173,845.44. This represents a 92.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Amy L. Ladd sold 336 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The stock was sold at an average price of $470.11, for a total transaction of $157,956.96. Following the completion of the transaction, the director owned 1,074 shares in the company, valued at $504,898.14. This represents a 23.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 45,224 shares of company stock worth $21,716,492 in the last three months. Corporate insiders own 0.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ISRG shares. Royal Bank Of Canada restated an “outperform” rating and set a $615.00 target price on shares of Intuitive Surgical in a research report on Tuesday, August 19th. The Goldman Sachs Group decreased their price objective on shares of Intuitive Surgical from $621.00 to $567.00 and set a “buy” rating for the company in a research note on Wednesday, October 1st. UBS Group raised their price objective on shares of Intuitive Surgical from $547.00 to $585.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 23rd. Piper Sandler reissued an “overweight” rating and issued a $595.00 price objective (up previously from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. Finally, BTIG Research reissued a “buy” rating and issued a $571.00 price objective on shares of Intuitive Surgical in a research note on Wednesday, October 1st. Fourteen research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $589.43.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.